Novozymes A/S (OTCMKTS:NVZMY) Upgraded to Strong-Buy at Barclays

Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) was upgraded by stock analysts at Barclays to a "strong-buy" rating in a research note issued on Monday,Zacks.com reports.

Several other analysts also recently weighed in on the company. Citigroup downgraded Novozymes A/S from a "neutral" rating to a "sell" rating in a research report on Thursday, October 17th. Berenberg Bank raised shares of Novozymes A/S to a "strong-buy" rating in a research report on Tuesday, September 24th.

Novozymes A/S Stock Up 2.2 %

OTCMKTS:NVZMY traded up $1.23 during mid-day trading on Monday, hitting $56.53. 23,033 shares of the stock traded hands, compared to its average volume of 12,694. The firm's 50 day moving average is $65.88 and its two-hundred day moving average is $63.85. Novozymes A/S has a 52 week low of $49.99 and a 52 week high of $72.50. The stock has a market capitalization of $26.47 billion, a price-to-earnings ratio of 35.78, a PEG ratio of 3.87 and a beta of 0.90.

Novozymes A/S Company Profile

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.